Oppenheimer Asset Management Inc. Has $241,000 Position in NeoGenomics, Inc. (NASDAQ:NEO)

Oppenheimer Asset Management Inc. raised its position in shares of NeoGenomics, Inc. (NASDAQ:NEOFree Report) by 44.9% in the third quarter, Holdings Channel reports. The fund owned 19,578 shares of the medical research company’s stock after buying an additional 6,062 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in NeoGenomics were worth $241,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in NeoGenomics by 0.9% during the first quarter. Vanguard Group Inc. now owns 12,970,503 shares of the medical research company’s stock valued at $157,592,000 after acquiring an additional 113,534 shares during the period. Brown Advisory Inc. boosted its holdings in NeoGenomics by 25.0% during the third quarter. Brown Advisory Inc. now owns 8,246,202 shares of the medical research company’s stock valued at $101,428,000 after acquiring an additional 1,651,717 shares during the period. State Street Corp boosted its holdings in NeoGenomics by 0.8% during the second quarter. State Street Corp now owns 4,926,392 shares of the medical research company’s stock valued at $79,167,000 after acquiring an additional 40,222 shares during the period. Dimensional Fund Advisors LP boosted its holdings in NeoGenomics by 10.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,980,374 shares of the medical research company’s stock valued at $47,895,000 after acquiring an additional 287,767 shares during the period. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in NeoGenomics by 13.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,916,935 shares of the medical research company’s stock valued at $26,953,000 after acquiring an additional 348,026 shares during the period. 91.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on NEO. TD Cowen decreased their price target on shares of NeoGenomics from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Friday, December 29th. Needham & Company LLC reiterated a “buy” rating and issued a $21.00 target price on shares of NeoGenomics in a research note on Thursday, December 28th. BTIG Research reduced their target price on shares of NeoGenomics from $25.00 to $21.00 and set a “buy” rating for the company in a research note on Friday, December 29th. Piper Sandler reduced their target price on shares of NeoGenomics from $23.00 to $18.00 and set an “overweight” rating for the company in a research note on Monday, October 16th. Finally, Morgan Stanley increased their target price on shares of NeoGenomics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.64.

Get Our Latest Stock Analysis on NeoGenomics

NeoGenomics Stock Performance

NASDAQ:NEO opened at $14.36 on Friday. NeoGenomics, Inc. has a 12-month low of $11.03 and a 12-month high of $21.22. The company has a quick ratio of 6.06, a current ratio of 6.32 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $1.83 billion, a PE ratio of -18.65 and a beta of 1.12. The firm has a 50-day moving average price of $16.93 and a 200 day moving average price of $15.52.

Insider Buying and Selling

In related news, General Counsel Alicia C. Olivo sold 2,669 shares of the stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $18.39, for a total value of $49,082.91. Following the completion of the transaction, the general counsel now owns 37,140 shares of the company’s stock, valued at $683,004.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.30% of the company’s stock.

NeoGenomics Company Profile

(Free Report)

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.

Read More

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEOFree Report).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.